Oral Care Composition Oleanic Acid Eugenol Hemostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral care products face challenges in effectively reducing gum bleeding and gingivitis while minimizing the risks associated with antibacterial agents, such as thromboembolic risks and drug interactions, and there is a need for natural or botanically-based active ingredients that provide improved antibacterial efficacy.
Innovation Solution
An oral care composition containing a hemostatic agent comprising a mixture of oleanic acid and eugenol, which enhances platelet aggregation and provides antibacterial effects, reducing gum bleeding by increasing platelet aggregation area and decreasing platelet rolling velocity, without the use of additional antibacterial agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibacterial agents are used in oral care products to reduce plaque and gingivitis, then gum bleeding is reduced, but thromboembolic risks and drug interactions increase
Solution Approach 1:
The patent changes the chemical parameters by using oleanic acid and eugenol instead of conventional antibacterial agents. Oleanic acid at concentrations of 0.01-1.0% and eugenol at 0.01-0.5% provides hemostatic effects through platelet aggregation mechanisms that are safer than traditional antibacterial agents, eliminating thromboembolic risks while maintaining gum bleeding reduction
Solution Approach 2:
The patent combines oleanic acid and eugenol in a composite hemostatic agent formulation. This composite approach synergistically enhances platelet aggregation and provides antibacterial effects without the harmful side effects of conventional single-agent antibacterial products, achieving both gum bleeding reduction and safety
2Reliability
If coagulant agents such as tranexamic acid are used to reduce gum bleeding, then gum bleeding is reduced, but thromboembolic and drug interaction risks increase
Solution Approach 1:
The patent changes the chemical mechanism from tranexamic acid (a synthetic coagulant) to natural hemostatic agents oleanic acid and eugenol. These natural compounds promote platelet aggregation through different biochemical pathways that do not carry thromboembolic risks, while still effectively reducing gum bleeding
Solution Approach 2:
The patent replaces expensive and risky synthetic coagulant agents with natural, safer alternatives. Oleanic acid and eugenol are derived from natural sources and provide the necessary hemostatic function without the serious side effects associated with synthetic coagulants like tranexamic acid
3Reliability
If conventional antibacterial agents are used in oral care products, then plaque and gingivitis are reduced, but antibacterial efficacy is affected by other active ingredients
Solution Approach 1:
The patent changes the active ingredients to oleanic acid and eugenol, which have stable antibacterial and hemostatic properties that are not significantly affected by interactions with other oral care ingredients. This formulation maintains consistent efficacy across different product compositions
Solution Approach 2:
The patent uses oleanic acid and eugenol as intermediary substances that mediate both antibacterial and hemostatic effects. These compounds act as effective intermediaries that provide dual functionality without the conflicting interactions that plague conventional multi-ingredient antibacterial formulations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oral care composition effectively reduces gum bleeding and provides enhanced antibacterial efficacy through the synergistic effects of oleanic acid and eugenol, improving hemostasis and antimicrobial activity.
Implementation Method 1
the hemostatic agent increases the platelet aggregation area by at least 10% over a control when tested according to example 1
Data Source
AI summary
Oral care compositions including a hemostatic agent, wherein the hemostatic agent includes a mixture of oleanic acid and eugenol. Methods of making and using these compositions are also described.